Yesterday (June 11th), there was news that the H.R.8333 proposal for the American Biological Safety Act was obstructed during the process of being included in the NDAA (2025 National Defense Authorization Act) legislation. At the annual shareholder meeting of WuXi AppTec on June 12th, the management responded that the company learned that the amendment to include the Biological Safety Act in the 2025 National Defense Authorization Act did not receive approval from the House of Representatives Rules Committee. Therefore, the Biological Safety Act will not currently enter the legislative agenda of the House of Representatives' 2025 National Defense Authorization Act, and its subsequent legislative path remains to be clarified. The company will continue to closely monitor the progress of related legislation. (Cailian Press)
药明康德回应：《生物安全法案》加入NDAA未获批准 暂不进入美众议院立法议程
Wuxi AppTec responded that the inclusion of the Biological Safety Act in the NDAA was not approved and will not currently enter the House of Representatives' legislative agenda.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.